ReviewJournal of bone oncology2026
Primary osseous malignancies of the foot: a comprehensive literature review and insights from a single-centre experience.
Review in Journal of bone oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: Primary malignant bone tumors of the foot are rare, with limited and heterogeneous data on.characteristics, management, and outcomes. This study aims to provide an overview of the epidemiology, treatment, and prognosis of these tumors through a systematic review and cohort analysis. Methods: PubMed, Embase, and Web of Science were searched for studies on osteosarcoma, Ewing's sarcoma, and chondrosarcoma of the foot. Studies in English or German including ≥ 10 patients with original data were eligible. Demographic, clinical, treatment, and outcome data were extracted. Additionally, a retrospective review was performed of all patients with foot malignancies (chondrosarcoma, Ewing sarcoma or osteosarcoma) treated at Amsterdam UMC (2013-2024). Data were pooled for analysis. Results: Eighteen studies met the inclusion criteria, comprising 884 patients including the single center cohort. Osteosarcoma, Ewing's sarcoma, and chondrosarcoma were the most common malignancies, most frequently affecting the calcaneus, metatarsals, and phalanges, respectively. The median diagnostic delay was 9 (IQR 6-14) months, with pain and swelling as the predominant presenting symptoms. Below-knee amputation was the most common surgical procedure, particularly for hindfoot tumors. Local recurrence rates were highest in osteosarcoma (19%), while Ewing's sarcoma had the highest incidence of metastatic disease (56%). Disease-specific mortality at last follow-up was 40% for osteosarcoma, 50% for Ewing's sarcoma, and 21% for chondrosarcoma. The single-centre cohort mirrored these findings, highlighting the challenges of delayed diagnosis and inadvertent surgery. Conclusion: Primary malignant bone tumors of the foot present significant diagnostic and therapeutic challenges, with high rates of recurrence and metastasis. Early recognition, referral to specialized centers, and multidisciplinary management are essential to improve outcomes. Future research should focus on prospective data collection, standardized reporting, and patient-reported outcomes to guide optimal care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.